|
|
|
|
| Symbol(s): |
PMC |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
PharMerica has a current Overall Rating of D (Negative). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| PharMerica has a current Overall Rating of D (Negative). Appreciation potential (31) is negative; Power Rating (9) is very low. Relative to the S&P 500 Composite, PharMerica Corporation has slightly more Value than Growth characteristics -- its appeal is likely to be to Capital Gain-oriented investors. PMC is of average investment quality. PharMerica's current technical position is very weak. PharMerica's Power Rating is 9. The trend in PMC's earnings estimates has been unfavorable...
| | |
|
|
